University of Auckland
University of Sydney
Professor Bill Denny
University of Auckland
Bill Denny received his MSc (1st class) in 1967 and his Ph.D (both under the direction of Professor Con Cambie) in 1969, from the University of Auckland. He then undertook post-doctoral training at Oxford University (UK) in the Dyson Perrins Laboratory, working under the direction of Professor Sir Ewart Jones. Bill then returned to New Zealand and joined the Auckland Cancer Society Research Centre (ACSRC) at the University of Auckland as a Senior Research Fellow, working on the development of the topo II inhibitor amsacrine, which was FDA-approved in 1984 in a collaboration with Parke-Davis. He is currently Director of the ACSRC, and in 2011 he was appointed to a Distinguished Professorship at the University of Auckland, and is a Principal Investigator in the Maurice Wilkins Centre (one of New Zealand’s national Centres of Research Excellence). The ACSRC under Bill’s leadership has to date brought a further 12 drugs to clinical trial, primarily for cancer but also for tuberculosis and leishmaniasis, with several more in late-stage development. In 2014 Bill was the recipient of the American Chemical Society's Division of Medicinal Chemistry Award. Other awards include the UK Royal Society of Chemistry Australasian Lectureship (1999), the UK Royal Society of Chemistry Adrien Albert Medal (2005), the Royal Australian Chemical Institute Adrien Albert Award (2006), the NZBio Biotechnologist of the Year award (2007) and the NZ Society for Oncology Commercialisation award (2012). He is an author/co-author on 660 publications and a co-inventor on 47 issued US patents, and is a scientific co-founder of the startup companies Proacta Inc and Pathway Therapeutics.
Associate Professor Lenka Munoz
University of Sydney
A/Prof Munoz received her PharmD (Doctor of Pharmacy, 2001) from Comenius University, Slovakia and her PhD in Medicinal Chemistry from the University of Bonn, Germany (2005). She completed her post-doctoral training in molecular pharmacology and preclinical drug development at the Northwestern University, Chicago, USA. After several years of career disruptions, she took up an appointment at the University of Sydney in 2011 as Lecturer in the Faculty of Medicine, and was promoted to Senior Lecturer in 2014 and to Associate Professor in 2017. She currently holds a Career Development Fellowship (2016-18) from the Cancer Institute NSW, and is Head of the Cell Signalling Laboratory at the Charles Perkins Centre. A/Prof Munoz’s research is centred on cell signalling pathways and kinase inhibitors, with a particularly strong focus on kinase inhibitors for the treatment of CNS diseases. Her laboratory uses medicinal chemistry, cell biology and molecular pharmacology platforms to develop novel CNS therapies.
A/Prof Munoz has been responsible for numerous contributions to the area of CNS drug discovery and development. She developed the first brain permeable p38 MAPK inhibitor. This inhibitor led to the development of a drug candidate against Alzheimer’s disease, currently in clinical trials. She was leading pre-clinical development of Minozac, an investigational drug against neuroinflammation (licensed and transferred to Neuromedix). More recently, she has advanced glioblastoma drug discovery through identification of a novel drug candidate licensed to Lin BioScience, and is leading development of this brain cancer technology in a newly established partnership between the University of Sydney and Lin BioScience. Since her PhD, she has spent 6 years FTE in research, during which time she has been awarded $3.7M in research funding and produced 26 high-quality publications in top-tier journals, e.g. Nature Reviews Drug Discovery, Journal of Medicinal Chemistry, Cancer Cell and Oncogene.
Professor Ronald J Quinn
Ron Quinn PhD is Professor of Chemistry. He received his B.Sc. and Ph.D. (with Ken Cavill) in Chemistry from UNSW. After postdoctoral training with Bob Pettit at Arizona State University, Richard Moore and Ted Norton at the University of Hawaii, and Rod Rickards at ANU he joined the Roche Research Institute for Marine Pharmacology in Sydney in 1974. He commenced his independent career in 1982 at Griffith University.
His interests focus on biodiscovery (natural products) for tuberculosis, malaria, Parkinson's disease, and prostate cancer; Fragment-based drug discovery (low MW natural products) using native state mass spectrometry; NMR metabolomics and Medicinal chemistry. He has ongoing interests in 'Ancient Knowledge:Modern Methods' applied to TCM via Joint Laboratories with the Shanghai Institute of Materia Medica and the Guangxi University of Chinese Medicine.
He has >290 publications and patents and 33 Ph.D. graduates.
Quinn’s honours and awards include the 2016 Paul J. Scheuer Award, 2016 Jack L. Beal Award, 2016 Planta Medica Most Innovative Paper, 2013 McCullough Robertson LSQ (Life Sciences Queensland) Industry Excellence Award, 2012 Queensland Museum Medal, 2007 Project of the Year, Medicines for Malaria Venture (MMV), 2004 Adrien Albert Award.
In 2003 he was elected FTSE and in 2010 Member of the Order of Australia (AM).
Until the 2017 Congress!
|Abstract submission opens Now Open|
|Registration opens Now Open|
|Abstract submission closes 30 March 2017|
|Early bird registration deadline 23 April 2017|
|RACI Centenary Congress 23-28 July 2017|